[Biotransformation and pharmacokinetics of AWD 26-06, 8-chloro- 5,10-dihydro-5-[bis(2-hydroxyethyl)aminoacetyl]-11H-dibenzo[b,c] [1,4]diazepin-11-one hydrochloride, in the rat].
Following p.o. and i.v. application of the 14C-labelled AWD 26-06 (6 mg/kg b.w.) with anticholinergic activity, blood levels (-24 h) and excretion (urine, feces-72 h; bile-7 h) were studied in Wistar rats. Intestinal absorption amounted to 30% of the dose administered in water solution. Elimination half-lives in blood were 0.6 h and (after Cmax 3-4 h p.a.) 8 h. Excretion was mainly by feces (unchanged drug and biliary excreted metabolites) and to less extent by urine.
Klemm
W
W
Geschäftsbereich Forschung und Entwicklung Arzneimittelwerk Dresden GmbH.
Morgenroth
U
U
Zerjatke
W
W
Joram
U
U
Gedan
A
A
Pfeifer
S
S
D000818:Animals; D001711:Biotransformation; D003984:Dibenzazepines / Q000378:metabolism* / Q000493:pharmacokinetics / Q000652:urine; D005243:Feces / Q000737:chemistry; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013056:Spectrophotometry, Ultraviolet
D003984:Dibenzazepines; C060713:AWD 26-06
Pharmakokinetik von AWD 26-06, 8-Chlor-5,10-dihydro-5-[bis(2- hydroxyethyl)aminoacetyl]-11H-dibenzo[b,e][1,4]diazepin-11-on- hydrochlorid an der Ratte.